High on innovation, rising demand and rejuvenated confidence to translate opportunities into success, the Indian pharmaceutical industry, which is among the top three in terms of volume globally, is growing leaps and bounds. By an estimate, the industry is all set to expand at a Compound Annual Growth Rate (CAGR) of 16 per cent to $55 billion by 2020. Much of this growth will depend on Indian pharma companies’ capacity to adopt Information Technology to drive their productivity, improve efficiency and maintain cost effectiveness.

In view of increased digital adoption, it is expected that Healthcare Information Technology (IT) market would expand more than 1.5 times by 2020 from its current value of $1 billion to meet the demand from pharma industry as well as other vertical of the healthcare sector….[Read More]

KEY SPEAKERS

Future Pharma For One World! Be a Global Leader in the Pharma

Past Partners in our Summits

eHealth 2016 Conferences Videos

Social Footprints

6790+
Facebook Likes
6200+
Linkedin Followers
1710+
Twitter Followers
80+
Our Conferences

Powered By

RSS Latest on eHEALTH Pharma

  • Lupin gets USFDA approval for generic Tamiflu capsules
    Pharma major Lupin can now market a generic version of Tamiflu capsules after it got approval from the US Food and Drug Administration (USFDA) to do so, it was revealed in an announcement recently. Tamilflu capsules are used to treat the viral disease flu (influenza). In a statement Lupin stated it got final approval from USFDA […]
  • Sanofi, Alnylam partner to treat rare genetic diseases
    Global Pharma companies, Sanofi and Alnylam have entered into an agreement for restructuring their Rare Nucleic Acid interface (RNAi) therapeutics for the treatment of rare genetic diseases. The agreement allows Sanofi to obtain global development and commercialisation rights to fitusiran — currently in development for the treatment of hemophilia A and B patients (bleeding disorder) […]
  • Dr.Reddy’s launches anti-cancer injection in US market
    Dr.Reddy’s Laboratories (DRL)  has launched anti-cancer injection in the United States market. Dr. Reddy’s Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran (melphalan hydrochloride) for Injection has been approved by the US Food and Drug Administration (USFDA), DRL said in a statement. The drug contains one single-dose clear glass vial of freeze-dried […]
  • Type 2 diabetes, a major health problem in India: study
    Type 2 diabetes is a major health problem in India and the prevalence has been escalating in the past few decades, finds a study conducted by a Mumbai-based diagnostic chain Metropolis Healthcare. In Type 2 diabetes, the body becomes resistant to the normal effects of insulin and gradually loses the capacity to produce enough insulin […]
  • Dr Reddy’s Laboratories launches anti-leukemia injection in US
    Pharmaceutical major Dr Reddy’s Laboratories Ltd has announced that it has launched Clofarabine injection, which is used to treat acute lymphoblastic leukemia (a type of cancer of the white blood cells), in the United States market after getting approval from the US Food and Drug Administration (USFDA). Clofarabine injection is a therapeutic equivalent generic version […]

Know More About Pharma CIO 2017